Predictors of psychedelic treatment outcomes among special operations forces veterans

There is a recognised mental health crisis among military Veterans, with Special Operations Forces Veterans (SOFV) facing particularly high risk due to repeated deployments, intense combat exposure and related neurocognitive and psychosocial sequelae. Existing traumafocused psychotherapies and approved pharmacotherapies for PTSD show limited effectiveness for many Veterans, suffer from high dropout rates, and often have delayed onset of benefit. In response, interest has grown in psychedelic-assisted therapies; early evidence suggests substances such as psilocybin, MDMA, ketamine and ibogaine/5-MeO-DMT can produce rapid and sometimes durable improvements in depression, trauma-related symptoms and substance use, but few studies have prospectively examined these interventions among Veterans and it remains unclear which baseline factors and psychological processes predict or mediate therapeutic gains. Xin and colleagues designed the present secondary analysis of prospectively collected clinical chart data to address three questions among SOFV who completed a combined ibogaine and 5-MeO-DMT residential programme in Mexico: (Aim 1) which pretreatment patient characteristics predict short-term (1-month) improvements in mental health functioning; (Aim 2) whether the intensity of acute psychedelic effects (personal meaningfulness, spiritual significance, psychological insightfulness) is associated with longer-term (up to 6 months) mental health and psychosocial outcomes; and (Aim 3) whether increases in psychological flexibility from pretreatment to 1 month mediate relationships between acute psychedelic effects and reductions in PTSD, depression and anxiety symptoms.

Data were collected as part of routine clinical practice at a residential psychedelic medicine programme between September 2019 and March 2021. Eligible patients were English-speaking U.S. SOFV who participated in a 3-day intensive intervention combining ibogaine and 5-MeO-DMT with individual and group-based preparation and integration therapy. The sequence was: Day 1 ibogaine preparation and dosing, Day 2 integration, and Day 3 5-MeO-DMT preparation, dosing and integration. The extracted text refers to previously published work for additional eligibility details. Participants were invited to complete self-report surveys at four time points: pretreatment, and 1-, 3- and 6-month follow-ups. From 99 attendees during the evaluable period, 86 completed the pretreatment survey; follow-up completions were 71 at 1 month, 62 at 3 months and 52 at 6 months, with 44 completing all four time points. The investigators used an intention-to-treat (ITT) approach to handle missing follow-up data, applying last-observation-carried-forward imputation for absent later time points. Outcome measures comprised standard self-report instruments: Satisfaction With Life Scale (5 items), PTSD Checklist-5 (PCL-5, 20 items), Patient Health Questionnaire-2 (PHQ-2), Generalized Anxiety Disorder-2 (GAD-2), the first three items of the Sheehan Disability Scale, the Medical Outcomes Study Cognitive Functioning subscale (6 items), the Depressive Symptom Index Suicidality Subscale (4 items), the Persisting Effects Questionnaire (ratings of personal meaningfulness, spiritual significance, psychological challenge and insight and 12-item psychosocial change items), and the Acceptance and Action Questionnaire (AAQ; 7 items) to index psychological inflexibility. Internal consistency reliabilities (Cronbach's alpha) reported for key scales were generally good to very good across time points (for example, PCL-5 baseline α = 0.92 to 1-month α = 0.96; AAQ baseline α = 0.92 to 6-month α = 0.95). Analyses used IBM SPSS Version 28. Change scores for outcomes were calculated by subtracting follow-up total scores (1- and 6-month) from pretreatment scores. For Aim 1, Pearson bivariate correlations assessed relationships between baseline characteristics and 1-month change scores. For Aim 2, Pearson correlations examined associations between acute psychedelic effect ratings and changes in mental health and psychosocial outcomes to 6 months. For Aim 3, mediation analyses tested whether change in psychological flexibility from pretreatment to 1 month mediated the link between acute psychedelic effect intensity and changes in PTSD, depression and anxiety from pretreatment to 1 month; these mediation tests employed the PROCESS v3.5 macro (Model 4) with 5,000 bootstrap resamples and 95% confidence intervals. Statistical significance was assessed at p = .05.

Sample characteristics: the evaluable sample (N = 86) was entirely male, predominantly White (87.2%) and non-Hispanic (89.5%), with mean age 42.9 years (SD = 7.9). Most had some college or higher education (about 90%), and 62% were married and living with a spouse. Military representation was chiefly Navy (84.0%), with the majority deployed from September 2001 onward. High rates of self-reported clinical concerns were present: memory/concentration problems 84.9%, traumatic brain injury 81.4%, depression 79.1%, anxiety 76.7%, PTSD 72.1%, and sleep problems 67.4%. Attrition across follow-ups left 71 participants at 1 month, 62 at 3 months and 52 at 6 months. Aim 1 — baseline predictors of 1-month change: younger age correlated with larger 1-month improvements in satisfaction with life, cognitive functioning, psychological flexibility, trauma symptoms, anxiety, and ratings of personal meaningfulness and spiritual significance of the acute experience. Greater baseline depression severity correlated with greater 1-month improvements in satisfaction with life, cognitive functioning, psychological flexibility, trauma symptoms, anxiety, personal meaningfulness and functional disability. Higher baseline anxiety was likewise associated with greater 1-month gains in satisfaction with life, cognitive functioning, psychological flexibility, trauma symptoms, depression, ratings of personal meaningfulness and psychological insightfulness, and disability. The extracted text does not report the exact correlation coefficients for these baseline predictor analyses. Aim 2 — acute psychedelic effects and 6-month outcomes: higher intensity acute effects (personal meaningfulness, spiritual significance, psychological insightfulness) were associated with larger improvements from pretreatment to 6 months in trauma symptoms (rs range = -0.33 to -0.26, p range = .005 to .031) and psychological flexibility (rs range = -0.34 to -0.32, p range = .004 to .006). Positive correlations were observed with satisfaction with life (rs range = 0.32 to 0.40, p range < .001 to .007) and with cognitive functioning (rs range = 0.27 to 0.35, p range = .003 to .024). Acute effects were also significantly correlated with a range of long-term psychosocial outcomes (well-being, life purpose/meaning, social relationships, attitudes about life, behavioural changes, spirituality, relationship to nature, views about the universe) with rs range = 0.24 to 0.43 and p range < .001 to .047. The authors note small prospective coefficients at 6 months. Aim 3 — mediation by psychological flexibility: mediation analyses found significant indirect effects of acute personal meaningfulness on decreases in PTSD (indirect effect = -0.23, 95% CI [-0.35, -0.11]), depression (indirect effect = -0.22, 95% CI [-0.35, -0.11]) and anxiety (indirect effect = -0.21, 95% CI [-0.33, -0.10]) via increases in psychological flexibility from pretreatment to 1 month. Acute spiritual significance showed significant indirect effects on PTSD (indirect effect = -0.18, 95% CI [-0.29, -0.08]), depression (indirect effect = -0.18, 95% CI [-0.29, -0.08]) and anxiety (indirect effect = -0.18, 95% CI [-0.29, -0.08]) through psychological flexibility. Psychological insightfulness likewise had indirect effects on PTSD (indirect effect = -0.21, 95% CI [-0.33, -0.10]), depression (indirect effect = -0.20, 95% CI [-0.32, -0.11]) and anxiety (indirect effect = -0.19, 95% CI [-0.30, -0.09]) via increased psychological flexibility. In sum, increases in psychological flexibility from pretreatment to 1 month statistically mediated the relationship between the intensity of acute psychedelic experiences and short-term reductions in trauma, depressive and anxiety symptoms.

Xin and colleagues interpret their findings as supporting three main points: first, younger age and greater baseline symptom severity (depression and anxiety) predicted larger short-term improvements, which the authors suggest could reflect shorter illness duration and greater neuroplasticity among younger participants or, conversely, greater potential for measurable change among those with higher initial symptom burden. They note that the association between baseline depression severity and improved outcomes is not uniformly consistent with prior non-psychedelic studies and merits further investigation. Second, the intensity of acute changes in consciousness occasioned by the combined ibogaine and 5-MeO-DMT treatment (personal meaningfulness, spiritual significance, psychological insightfulness) was related to more favourable long-term mental health and psychosocial trajectories up to 6 months. The authors place these results alongside earlier clinical and naturalistic studies that have linked mystical or meaningful experiences with enduring improvements in wellbeing and symptomatology, while acknowledging that some associations (for example, with depression) were evident at 1 month but not sustained at 6 months. Third, the mediation analyses indicate that increases in psychological flexibility may be a plausible mechanism linking acute psychedelic experiences to reductions in PTSD, depression and anxiety symptoms. The authors point to convergent cross-sectional and prospective findings in the psychedelic literature and propose that combining psychedelic administration with psychotherapies that explicitly target psychological flexibility (for example, acceptance and commitment therapy) could be a fruitful avenue for future trials. The study's limitations are emphasised. The sample lacked demographic diversity (entirely male, predominantly White) and no control or comparator groups were used, so causal inference about the combined treatment cannot be established. Self-selection bias was likely, because many participants had previously pursued other treatments. The mediation approach used PROCESS, which estimates equations separately and may introduce bias relative to simultaneous-equation methods such as structural equation modelling; however SEM would require larger samples than available. Attrition and a modest sample size likely reduced statistical power and contributed to relatively small effect coefficients for some prospective associations. The authors recommend future controlled studies with larger, more diverse samples, use of comparator groups (for instance single-agent or alternative ordering of agents), and application of methods that can better manage measurement error and mediation estimation bias.

The authors conclude that combined ibogaine and 5-MeO-DMT therapy administered in a short 3-day residential programme was associated with substantial self-reported improvements across multiple mental health and cognitive domains among SOFV. They highlight that the subjective intensity of acute psychedelic effects and increases in psychological flexibility were key factors associated with positive outcomes, and that younger age and greater baseline anxiety/depression were predictive of larger short-term gains. Xin and colleagues call for prospectively designed cohort studies and randomised trials with control groups, larger and more diverse samples, and investigations of mechanisms such as psychological flexibility to better establish safety, efficacy and causal pathways for this treatment approach among Veterans.